MNG956
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.413
- TNFA_SIGNALING_VIA_NFKB+0.413
- COAGULATION+0.344
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.339
- ESTROGEN_RESPONSE_LATE+0.279
- XENOBIOTIC_METABOLISM+0.271
- UV_RESPONSE_UP+0.263
- KRAS_SIGNALING_DN+0.251
- APOPTOSIS+0.227
- ESTROGEN_RESPONSE_EARLY+0.225
Top 10 suppressed
- MITOTIC_SPINDLE-0.488
- WNT_BETA_CATENIN_SIGNALING-0.457
- G2M_CHECKPOINT-0.455
- UV_RESPONSE_DN-0.400
- HEDGEHOG_SIGNALING-0.367
- PROTEIN_SECRETION-0.321
- E2F_TARGETS-0.283
- ANGIOGENESIS-0.250
- APICAL_JUNCTION-0.215
- PI3K_AKT_MTOR_SIGNALING-0.205
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A6FQ-01A-11R-A31O-07 | — | B | 0.796 |
| 2 | TCGA-E9-A6HE-01A-11R-A31O-07 | — | B | 0.777 |
| 3 | MDT-AP-2299 | Med | Medulloblastoma | 0.753 |
| 4 | TCGA-AC-A62Y-01A-11R-A29R-07 | — | A | 0.751 |
| 5 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.750 |
| 6 | TCGA-LL-A9Q3-01A-11R-A41B-07 | — | B | 0.747 |
| 7 | ERR2598335 | fetal | fetal | 0.746 |
| 8 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.744 |
| 9 | MNG1160 | — | — | 0.739 |
| 10 | SRR5088903 | — | — | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.413 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.413 | Inavolisib | — uncovered |
| COAGULATION | 0.344 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.339 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.279 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.271 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.263 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.251 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.227 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.225 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.201 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.197 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.194 | Idelalisib | — uncovered |
| HYPOXIA | 0.185 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.179 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.152 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.144 | Inavolisib | — uncovered |
| PEROXISOME | 0.116 | Idelalisib | — uncovered |
| MYOGENESIS | 0.109 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.106 | Remibrutinib | — uncovered |